Protein Kinase A-Dependent Synergism between GATA Factors and the Nuclear Receptor, Liver Receptor Homolog-1, Regulates Human Aromatase (CYP19) PII Promoter Activity in Breast Cancer Cells
Authors:
- Hiroaki TaniguchiHiroaki Taniguchi
- Robert S. VigerRVRobert S. Viger
Open Access
- 1 November 2005
- journal article
- Published by The Endocrine Society in Endocrinology
- Vol. 146 (11) , 4905-4916
Abstract
Cancers, including that of the breast, are the result of multiple contributing factors including aberrant gene expression. Indeed, the CYP19 gene encoding P450 aromatase, the key enzyme for estrogen biosynthesis, is up-regulated in breast tumors predominantly via the cAMP-responsive gonad-type PII promoter, ultimately leading to increased intratumoral estrogen production and tumor growth. Thus, identifying the molecular factors involved in aromatase PII promoter regulation is essential for our understanding and treatment of the disease. Because we have previously shown activity of the murine aromatase PII promoter to be markedly up-regulated by GATA factors with respect to the gonads, we hypothesized that GATA factors are also key determinants of human PII promoter-driven aromatase transcription in breast tumors. We now show that GATA3 and GATA4 are indeed expressed in several breast cancer cells lines. Consistent with the cAMP dependence of the PII promoter, activation elicited by GATA3 or GATA4 alone and the striking synergism between GATA3 or GATA4 and the nuclear receptor liver receptor homolog (LRH)-1 was intimately linked to forskolin treatment or overexpression of protein kinase A (PKA) catalytic subunit. PKA-mediated phosphorylation increases the interaction between GATA3 and LRH-1 and the requirement for PKA in aromatase PII promoter stimulation involves at least three specific amino acid residues: GATA3 Ser308, GATA4 Ser261, and LRH-1 Ser469. Finally, we show that the human LRH-1 promoter is itself a target for GATA factors. Thus, taken together, our results suggest that GATA factors likely contribute to aberrant aromatase expression in breast tumors through two distinct, yet complementary mechanisms.Keywords
This publication has 62 references indexed in Scilit:
- The Prostaglandin E2 Receptor EP2 Is Required for Cyclooxygenase 2–Mediated Mammary HyperplasiaCancer Research, 2005
- Interaction between GATA and the C/EBP Family of Transcription Factors Is Critical in GATA-Mediated Suppression of Adipocyte DifferentiationMolecular and Cellular Biology, 2005
- Identification and validation of an ERBB2 gene expression signature in breast cancersOncogene, 2004
- Transcription Factor GATA-4 Is Activated by Phosphorylation of Serine 261 via the cAMP/Protein Kinase A Signaling Pathway in Gonadal CellsJournal of Biological Chemistry, 2003
- Rho/ROCK Pathway Contributes to the Activation of Extracellular Signal-regulated Kinase/GATA-4 during Myocardial Cell HypertrophyJournal of Biological Chemistry, 2002
- The Transcription Factor GATA4 Is Activated by Extracellular Signal-Regulated Kinase 1- and 2-Mediated Phosphorylation of Serine 105 in CardiomyocytesMolecular and Cellular Biology, 2001
- Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary cultureThe Journal of Steroid Biochemistry and Molecular Biology, 1997
- Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reactionThe Journal of Steroid Biochemistry and Molecular Biology, 1996
- Steroid dynamics in the normal and carcinomatous mammary glandJournal of Steroid Biochemistry, 1986
- Autocrine and paracrine growth regulation of human breast cancerJournal of Steroid Biochemistry, 1986